Advances of Microneedles for Cancer Diagnosis and Therapy

Abstract

As the global incidence of cancer continues to rise, the need for innovative and precisive alternatives to conventional diagnostic and therapeutic methods has become increasingly urgent. Microneedles (MNs), comprising arrays of micron-scale projections, have emerged as a platform that provides a painless and minimally invasive system for interstitial fluid analysis and transdermal drug delivery. This technology demonstrates potential in cancer diagnostics through continuous biomarker monitoring using integrated biosensors, while enabling controlled release of chemotherapeutics, photothermal/photodynamic, and immunotherapeutic agents. Over the past decades, significant advancements in technology, materials, and medical applications have been achieved in the MN field, which have attracted increasing attention of reseachers. Currently, several MN-based strategies registered on ClinicalTrials.gov are actively investigating their applications in medince, positioning them as a promising new tool for cancer treatment and diagnosis. This review offers a comprehensive summary of the classification, design, fabrication materials, and techniques of MNs, along with their medical applications in cancer diagnosis, therapy, and the management of cancer-associated pain and hair loss. Furthermore, this review summarized ongoing clinical trials in investigating MN-based therapies for cancer patients. And challenges, future perspectives of applying MNs in cancer theranostics are also presented.

Keywords

cancer / diagnosis / microneedles / treatment

References

[1] R. L. Siegel, A. N. Giaquinto, and A. Jemal, “Cancer Statistics, 2024,” CA: A Cancer Journal for Clinicians 74, no. 1 (2024): 12–49.

[2] D. Crosby, S. Bhatia, K. M. Brindle, et al., “Early Detection of Cancer,” Science 375, no. 6586 (2022): eaay9040.

[3] N. Sato, S. Takano, H. Yoshitomi, et al., “Needle Tract Seeding Recurrence of Pancreatic Cancer in the Gastric Wall With Paragastric Lymph Node Metastasis After Endoscopic Ultrasound-Guided Fine Needle Aspiration Followed by Pancreatectomy: A Case Report and Literature Review,” BMC Gastroenterology 20, no. 1 (2020): 13.

[4] R. Y. Gao, B. H. Wu, X. Y. Shen, et al., “Overlooked Risk for Needle Tract Seeding Following Endoscopic Ultrasound-Guided Minimally Invasive Tissue Acquisition,” World Journal of Gastroenterology 26, no. 40 (2020): 6182–6194.

[5] Y. Backes, T. C. J. Seerden, R. S. F. E. van Gestel, et al., “Tumor Seeding During Colonoscopy as a Possible Cause for Metachronous Colorectal Cancer,” Gastroenterology 157, no. 5 (2019): 1222–1232.e4.

[6] J. J. Chabon, E. G. Hamilton, D. M. Kurtz, et al., “Integrating Genomic Features for Non-Invasive Early Lung Cancer Detection,” Nature 580, no. 7802 (2020): 245–251.

[7] J. Wu, S. Hu, L. Zhang, et al., “Tumor Circulome in the Liquid Biopsies for Cancer Diagnosis and Prognosis,” Theranostics 10, no. 10 (2020): 4544–4556.

[8] H. C. Ates, A. Brunauer, F. von Stetten, et al., “Integrated Devices for Non-Invasive Diagnostics,” Advanced Functional Materials 31, no. 15 (2021): 2010388.

[9] Y. Sun, Z. Guo, X. Liu, et al., “Noninvasive Urinary Protein Signatures Associated With Colorectal Cancer Diagnosis and Metastasis,” Nature Communications 13, no. 1 (2022): 2757.

[10] F. Montagne, F. Guisier, N. Venissac, and J. M. Baste, “The Role of Surgery in Lung Cancer Treatment: Present Indications and Future Perspectives—State of the Art,” Cancers 13, no. 15 (2021): 3711.

[11] R. A. Chandra, F. K. Keane, F. E. M. Voncken, and C. R. Thomas, “Contemporary Radiotherapy: Present and Future,” The Lancet 398, no. 10295 (2021): 171–184.

[12] N. Behranvand, F. Nasri, R. Zolfaghari Emameh, et al., “Chemotherapy: A Double-Edged Sword in Cancer Treatment,” Cancer Immunology, Immunotherapy 71, no. 3 (2022): 507–526.

[13] Y. Zhang and Z. Zhang, “The History and Advances in Cancer Immunotherapy: Understanding the Characteristics of Tumor-Infiltrating Immune Cells and Their Therapeutic Implications,” Cellular & Molecular Immunology 17, no. 8 (2020): 807–821.

[14] D. Paran, Y. Herishanu, O. Elkayam, L. Shopin, and R. Ben-Ami, “Venous and Arterial Thrombosis Following Administration of Intravenous Immunoglobulins,” Blood Coagulation & Fibrinolysis 16, no. 5 (2005): 313–318.

[15] S. Machat, E. Eisenhuber, G. Pfarl, et al., “Complications of Central Venous Port Systems: A Pictorial Review,” Insights into Imaging 10, no. 1 (2019): 86.

[16] N. S. Evans and E. V. Ratchford, “Catheter-Related Venous Thrombosis,” Vascular Medicine 23, no. 4 (2018): 411–413.

[17] M. Zheng, T. Sheng, J. Yu, Z. Gu, and C. Xu, “Microneedle Biomedical Devices,” Nature Reviews Bioengineering 2 (2024): 324–342.

[18] R. Li, L. Zhang, X. Jiang, et al., “3D-printed Microneedle Arrays for Drug Delivery,” Journal of Controlled Release 350 (2022): 933–948.

[19] D. Zhi, T. Yang, T. Zhang, M. Yang, S. Zhang, and R. F. Donnelly, “Microneedles for Gene and Drug Delivery in Skin Cancer Therapy,” Journal of Controlled Release 335 (2021): 158–177.

[20] D. Ghanbariamin, M. Samandari, P. Ghelich, et al., “Cleanroom-Free Fabrication of Microneedles for Multimodal Drug Delivery,” Small 19, no. 29 (2023): 2207131.

[21] B. Z. Chen, Y. T. He, Z. Q. Zhao, et al., “Strategies to Develop Polymeric Microneedles for Controlled Drug Release,” Advanced Drug Delivery Reviews 203 (2023): 115109.

[22] M. Friedel, I. A. P. Thompson, G. Kasting, et al., “Opportunities and Challenges in the Diagnostic Utility of Dermal Interstitial Fluid,” Nature Biomedical Engineering 7, no. 12 (2023): 1541–1555.

[23] T. Terkelsen, F. Russo, P. Gromov, et al., “Secreted Breast Tumor Interstitial Fluid Micrornas and Their Target Genes Are Associated With Triple-Negative Breast Cancer, Tumor Grade, and Immune Infiltration,” Breast Cancer Research 22, no. 1 (2020): 73.

[24] X. Dong, B. Ma, L. Lei, et al., “Three-Dimensional Photonic Nitrocellulose for Minimally Invasive Detection of Biomarker in Tumor Interstitial Fluid,” Chemical Engineering Journal 432 (2022): 134234.

[25] B. Yang, X. Fang, and J. Kong, “Engineered Microneedles for Interstitial Fluid Cell-Free DNA Capture and Sensing Using Iontophoretic Dual-Extraction Wearable Patch,” Advanced Functional Materials 30, no. 24 (2020): 2000591.

[26] Z. Wang, J. Luan, A. Seth, et al., “Microneedle Patch for the Ultrasensitive Quantification of Protein Biomarkers in Interstitial Fluid,” Nature Biomedical Engineering 5, no. 1 (2021): 64–76.

[27] F. Tehrani, H. Teymourian, B. Wuerstle, et al., “An Integrated Wearable Microneedle Array for the Continuous Monitoring of Multiple Biomarkers in Interstitial Fluid,” Nature Biomedical Engineering 6, no. 11 (2022): 1214–1224.

[28] H. Yang, X. Jiang, Y. Zeng, et al., “A Swellable Bilateral Microneedle Patch With Core-Shell Structure for Rapid Lactate Analysis and Early Melanoma Diagnosis,” Chemical Engineering Journal 455 (2023): 140730.

[29] H. Huang, M. Qu, Y. Zhou, et al., “A Microneedle Patch for Breast Cancer Screening via Minimally Invasive Interstitial Fluid Sampling,” Chemical Engineering Journal 472 (2023): 145036.

[30] H. Zheng, F. Keyvani, S. Sadeghzadeh, et al., “Rapid miRNA Detection in Skin Interstitial Fluid Using a Hydrogel Microneedle Patch Integrated With Dna Probes and Graphene Oxide,” Lab on a Chip 24, no. 21 (2024): 4989–4997.

[31] H. Li, Z. Peng, Y. Song, et al., “Study of the Permeation-Promoting Effect and Mechanism of Solid Microneedles on Different Properties of Drugs,” Drug Delivery 30, no. 1 (2023): 2165737.

[32] N. Tariq, M. W. Ashraf, and S. Tayyaba, “A Review on Solid Microneedles for Biomedical Applications,” Journal of Pharmaceutical Innovation 17, no. 4 (2022): 1464–1483.

[33] S. Economidou, C. Pissinato Pere, M. Okereke, and D. Douroumis, “Optimisation of Design and Manufacturing Parameters of 3D Printed Solid Microneedles for Improved Strength, Sharpness, and Drug Delivery,” Micromachines 12, no. 2 (2021): 117.

[34] X. Liu, R. Li, X. Yuan, et al., “Fast Customization of Microneedle Arrays by Static Optical Projection Lithography,” ACS Applied Materials & Interfaces 13, no. 50 (2021): 60522–60530.

[35] H. S. Gill and M. R. Prausnitz, “Coated Microneedles for Transdermal Delivery,” Journal of Controlled Release 117, no. 2 (2007): 227–237.

[36] R. S. J. Ingrole, E. Azizoglu, M. Dul, J. C. Birchall, H. S. Gill, and M. R. Prausnitz, “Trends of Microneedle Technology in the Scientific Literature, Patents, Clinical Trials and Internet Activity,” Biomaterials 267 (2021): 120491.

[37] Á. Cárcamo-Martínez, B. Mallon, J. Domínguez-Robles, L. K. Vora, Q. K. Anjani, and R. F. Donnelly, “Hollow Microneedles: A Perspective in Biomedical Applications,” International Journal of Pharmaceutics 599 (2021): 120455.

[38] R. Li, X. Liu, X. Yuan, et al., “Fast Customization of Hollow Microneedle Patches for Insulin Delivery,” International Journal of Bioprinting 8, no. 2 (2022): 553.

[39] Z. Sartawi, C. Blackshields, and W. Faisal, “Dissolving Microneedles: Applications and Growing Therapeutic Potential,” Journal of Controlled Release 348 (2022): 186–205.

[40] Z. Sartawi, C. Blackshields, and W. Faisal, “Dissolving Microneedles: Applications and Growing Therapeutic Potential,” Journal of Controlled Release 348 (2022): 186–205.

[41] J. Chudzińska, A. Wawrzyńczak, and A. Feliczak-Guzik, “Microneedles Based on a Biodegradable Polymer—Hyaluronic Acid,” Polymers 16, no. 10 (2024): 1396.

[42] X. Yu, J. Zhao, and D. Fan, “The Progress in the Application of Dissolving Microneedles in Biomedicine,” Polymers 15, no. 20 (2023): 4059.

[43] T. Bauleth-Ramos, N. El-Sayed, F. Fontana, M. Lobita, M. A. Shahbazi, and H. A. Santos, “Recent Approaches for Enhancing the Performance of Dissolving Microneedles in Drug Delivery Applications,” Materials Today 63 (2023): 239–287.

[44] G. Wang, K. Kato, I. Aoki, et al., “Transdermal Drug Delivery Using a Porous Microneedle Device Driven by a Hydrogel Electroosmotic Pump,” Journal of Materials Chemistry B 12, no. 6 (2024): 1490–1494, https://doi.org/10.1039/D3TB02208K.

[45] L. Bao, J. Park, G. Bonfante, and B. Kim, “Recent Advances in Porous Microneedles: Materials, Fabrication, and Transdermal Applications,” Drug Delivery and Translational Research 12, no. 2 (2022): 395–414.

[46] H. Wei, S. Liu, Z. Tong, et al., “Hydrogel-Based Microneedles of Chitosan Derivatives for Drug Delivery,” Reactive and Functional Polymers 172 (2022): 105200.

[47] Q. K. Anjani, A. D. Permana, Á. Cárcamo-Martínez, et al., “Versatility of Hydrogel-Forming Microneedles in In Vitro Transdermal Delivery of Tuberculosis Drugs,” European Journal of Pharmaceutics and Biopharmaceutics 158 (2021): 294–312.

[48] R. F. Donnelly, T. R. R. Singh, M. J. Garland, et al., “Hydrogel-Forming Microneedle Arrays for Enhanced Transdermal Drug Delivery,” Advanced Functional Materials 22, no. 23 (2012): 4879–4890.

[49] M. Zheng, T. Hu, Y. Yang, et al., “In Situ-Formed Cryomicroneedles for Intradermal Cell Delivery,” NPG Asia Materials 16, no. 1 (2024): 11.

[50] R. Ali, P. Mehta, M. Arshad, I. Kucuk, M. W. Chang, and Z. Ahmad, “Transdermal Microneedles—A Materials Perspective,” AAPS PharmSciTech 21, no. 1 (2019): 12.

[51] F. K. Aldawood, A. Andar, and S. Desai, “A Comprehensive Review of Microneedles: Types, Materials, Processes, Characterizations and Applications,” Polymers 13, no. 16 (2021): 2815.

[52] H. E. Zainal Abidin, P. C. Ooi, T. Y. Tiong, et al., “Stress and Deformation of Optimally Shaped Silicon Microneedles for Transdermal Drug Delivery,” Journal of Pharmaceutical Sciences 109, no. 8 (2020): 2485–2492.

[53] V. Ghate, A. Renjith, K. Badnikar, et al., “Single Step Fabrication of Hollow Microneedles and An Experimental Package for Controlled Drug Delivery,” International Journal of Pharmaceutics 632 (2023): 122546.

[54] X. Peng Zhang, Y. Ting He, W. Xuan Li, et al., “An Update on Biomaterials as Microneedle Matrixes for Biomedical Applications,” Journal of Materials Chemistry B 10, no. 32 (2022): 6059–6077.

[55] M. C. Kouassi, A. B. Abdallah, S. Nouira, et al., “FDM Printing of Microneedles Based on Biocompatible and Biodegradable Thermoplastic Polymers,” Journal of Applied Polymer Science 141, no. 41 (2024): e56067.

[56] N. Dabholkar, S. Gorantla, T. Waghule, et al., “Biodegradable Microneedles Fabricated With Carbohydrates and Proteins: Revolutionary Approach for Transdermal Drug Delivery,” International Journal of Biological Macromolecules 170 (2021): 602–621.

[57] J. M. Loh, Y. J. L. Lim, J. T. Tay, H. M. Cheng, H. L. Tey, and K. Liang, “Design and Fabrication of Customizable Microneedles Enabled by 3D Printing for Biomedical Applications,” Bioactive Materials 32 (2024): 222–241.

[58] Z. F. Rad, P. D. Prewett, and G. J. Davies, “An Overview of Microneedle Applications, Materials, and Fabrication Methods,” Beilstein Journal of Nanotechnology 12, no. 1 (2021): 1034–1046.

[59] A. Tucak, M. Sirbubalo, L. Hindija, et al., “Microneedles: Characteristics, Materials, Production Methods and Commercial Development,” Micromachines 11, no. 11 (2020): 961.

[60] Z. Faraji Rad, P. D. Prewett, and G. J. Davies, “High-Resolution Two-Photon Polymerization: The Most Versatile Technique for the Fabrication of Microneedle Arrays,” Microsystems & Nanoengineering 7, no. 1 (2021): 71.

[61] A. A. Biswas, M. R. Dhondale, A. K. Agrawal, D. R. Serrano, B. Mishra, and D. Kumar, “Advancements in Microneedle Fabrication Techniques: Artificial Intelligence Assisted 3D-printing Technology,” Drug Delivery and Translational Research 14, no. 6 (2024): 1458–1479.

[62] M. Shikida, Y. Hasegawa, M. S. A. Farisi, M. Matsushima, and T. Kawabe, “Advancements in MEMS Technology for Medical Applications: Microneedles and Miniaturized Sensors,” Japanese Journal of Applied Physics 61, no. SA (2021): SA0803.

[63] I. Eş, A. Kafadenk, M. B. Gormus, and F. Inci, “Xenon Difluoride Dry Etching for the Microfabrication of Solid Microneedles as a Potential Strategy in Transdermal Drug Delivery,” Small 19 (2023): 2206510.

[64] A. Malek-Khatabi, Z. Faraji Rad, M. Rad-Malekshahi, and H. Akbarijavar, “Development of Dissolvable Microneedle Patches by CNC Machining and Micromolding for Drug Delivery,” Materials Letters 330 (2023): 133328.

[65] F. K. Aldawood, A. Andar, and S. Desai, “Investigating Laser Ablation Process Parameters for the Fabrication of Customized Microneedle Arrays for Therapeutic Applications,” Pharmaceutics 16, no. 7 (2024): 885.

[66] V. Onesto, C. Di Natale, M. Profeta, P. A. Netti, and R. Vecchione, “Engineered PLGA-PVP/VA Based Formulations to Produce Electro-Drawn Fast Biodegradable Microneedles for Labile Biomolecule Delivery,” Progress in Biomaterials 9, no. 4 (2020): 203–217.

[67] Y. Li, K. Chen, Y. Pang, et al., “Multifunctional Microneedle Patches via Direct Ink Drawing of Nanocomposite Inks for Personalized Transdermal Drug Delivery,” ACS Nano 19 (2023): 19925–19937.

[68] S. Terashima, C. Tatsukawa, M. Suzuki, T. Takahashi, and S. Aoyagi, “Twice Stretched Fabrication of Polylactic Acid Microneedle Arrays Using Drawing Lithography,” International Journal of Precision Engineering and Manufacturing 21, no. 10 (2020): 1933–1942.

[69] H. Ako, J. O'Mahony, H. Hughes, P. McLoughlin, and N. J. O'Reilly, “A Novel Approach to the Manufacture of Dissolving Microneedles Arrays Using Aerosol Jet Printing,” Applied Materials Today 35 (2023): 101958.

[70] A. Sachan, R. J. Sachan, J. Lu, et al., “Injection Molding for Manufacturing of Solid Poly(L-Lactide-Co-Glycolide) Microneedles,” MRS Advances 6, no. 3 (2021): 61–65.

[71] B. Bediz, E. Korkmaz, R. Khilwani, et al., “Dissolvable Microneedle Arrays for Intradermal Delivery of Biologics: Fabrication and Application,” Pharmaceutical Research 31, no. 1 (2014): 117–135.

[72] M. Sirbubalo, A. Tucak, K. Muhamedagic, et al., “3D Printing—A ‘Touch-Button’ Approach to Manufacture Microneedles for Transdermal Drug Delivery,” Pharmaceutics 13, no. 7 (2021): 924.

[73] J. R. Tumbleston, D. Shirvanyants, N. Ermoshkin, et al., “Continuous Liquid Interface Production of 3D Objects,” Science 347, no. 6228 (2015): 1349–1352.

[74] A. Ovsianikov, B. Chichkov, P. Mente, N. A. Monteiro-Riviere, A. Doraiswamy, and R. J. Narayan, “Two Photon Polymerization of Polymer–Ceramic Hybrid Materials for Transdermal Drug Delivery,” Applied Ceramic Technology 4 (2007): 22–29.

[75] G. Xu, Y. Mao, T. Jiang, B. Gao, and B. He, “Structural Design Strategies of Microneedle-Based Vaccines for Transdermal Immunity Augmentation,” Journal of Controlled Release 351 (2022): 907–922.

[76] F. Henriquez, J. O. Morales-Ferreiro, and D. Celentano, “Structural Evaluation by the Finite-Element Method of Hollow Microneedle Geometries for Drug Delivery,” Advanced Engineering Materials 24, no. 10 (2022): 220049.

[77] K. T. Chang, Y. K. Shen, F. Y. Fan, Y. Lin, and S. C. Kang, “Optimal Design and Fabrication of a Microneedle Arrays Patch,” Journal of Manufacturing Processes 54 (2020): 274–285.

[78] P. Makvandi, M. Kirkby, A. R. J. Hutton, et al., “Engineering Microneedle Patches for Improved Penetration: Analysis, Skin Models and Factors Affecting Needle Insertion,” Nano-Micro Letters 13, no. 1 (2021): 93.

[79] B. Jia, T. Xia, X. Wang, Y. Xu, and Z. Guo, “Morphology Design of Polymer Microneedle Arrays: Key Factors From the Application Perspective,” Journal of Drug Delivery Science and Technology 88 (2023): 104883.

[80] H. Chang, S. W. T. Chew, M. Zheng, et al., “Cryomicroneedles for Transdermal Cell Delivery,” Nature Biomedical Engineering 5, no. 9 (2021): 1008–1018.

[81] X. Zhang, X. Fu, G. Chen, Y. Wang, and Y. Zhao, “Versatile Ice Microneedles for Transdermal Delivery of Diverse Actives,” Advanced Science 8, no. 17 (2021): 2101210.

[82] H. Hricak, M. Abdel-Wahab, R. Atun, et al., “Medical Imaging and Nuclear Medicine: A Lancet Oncology Commission,” Lancet Oncology 22, no. 4 (2021): e136–e172.

[83] S. N. Lone, S. Nisar, T. Masoodi, et al., “Liquid Biopsy: A Step Closer to Transform Diagnosis, Prognosis and Future of Cancer Treatments,” Molecular Cancer 21, no. 1 (2022): 79.

[84] M. Y. Lu, T. Y. Chen, D. F. K. Williamson, et al., “AI-Based Pathology Predicts Origins for Cancers of Unknown Primary,” Nature 594, no. 7861 (2021): 106–110.

[85] K. Rahbar, H. Seifarth, M. Schäfers, et al., “Differentiation of Malignant and Benign Cardiac Tumors Using 18F-FDG PET/CT,” Journal of Nuclear Medicine 53, no. 6 (2012): 856–863.

[86] Y. Li, Y. Zhang, E. Zhang, et al., “Differential Diagnosis of Benign and Malignant Vertebral Fracture on CT Using Deep Learning,” European Radiology 31, no. 12 (2021): 9612–9619.

[87] E. Birgin, C. Yang, S. Hetjens, C. Reissfelder, P. Hohenberger, and N. N. Rahbari, “Core Needle Biopsy Versus Incisional Biopsy for Differentiation of Soft-Tissue Sarcomas: A Systematic Review and Meta-Analysis,” Cancer 126, no. 9 (2020): 1917–1928.

[88] R. Lawrence, M. Watters, C. R. Davies, K. Pantel, and Y. J. Lu, “Circulating Tumour Cells for Early Detection of Clinically Relevant Cancer,” Nature Reviews Clinical Oncology 20, no. 7 (2023): 487–500.

[89] S. Cai, T. Pataillot-Meakin, A. Shibakawa, et al., “Single-Molecule Amplification-Free Multiplexed Detection of Circulating microRNA Cancer Biomarkers From Serum,” Nature Communications 12, no. 1 (2021): 3515.

[90] W. T. Liu, Y. P. Cao, X. H. Zhou, and D. Han, “Interstitial Fluid Behavior and Diseases,” Advanced Science 9, no. 6 (2022): 2100617.

[91] A. Chachaj, R. Matkowski, G. Gröbner, A. Szuba, and I. Dudka, “Metabolomics of Interstitial Fluid, Plasma and Urine in Patients With Arterial Hypertension: New Insights into the Underlying Mechanisms,” Diagnostics 10, no. 11 (2020): 936.

[92] X. Yuan, O. Ouaskioud, X. Yin, et al., “Epidermal Wearable Biosensors for the Continuous Monitoring of Biomarkers of Chronic Disease in Interstitial Fluid,” Micromachines 14, no. 7 (2023): 1452.

[93] Q. Yang, Y. Wang, T. Liu, et al., “Microneedle Array Encapsulated With Programmed DNA Hydrogels for Rapidly Sampling and Sensitively Sensing of Specific microRNA in Dermal Interstitial Fluid,” ACS Nano 16 (2022): 18366–18375.

[94] L. Chen, C. Zhang, J. Xiao, et al., “Local Extraction and Detection of Early Stage Breast Cancers Through a Microneedle and Nano-Ag/MBL Film Based Painless and Blood-Free Strategy,” Materials Science & Engineering, C: Materials for Biological Applications 109 (2020): 110402.

[95] X. Huang, L. Chen, T. Sha, et al., “In Situ Tyrosinase Monitoring by Wearable Microneedle Patch Toward Clinical Melanoma Screening,” ACS Nano 17, no. 20 (2023): 20073–20086.

[96] G. Wang, Y. Zhang, H. K. Kwong, et al., “On-Site Melanoma Diagnosis Utilizing a Swellable Microneedle-Assisted Skin Interstitial Fluid Sampling and a Microfluidic Particle Dam for Visual Quantification of S100A1,” Advanced Science 11, no. 16 (2024): 2306188.

[97] Z. Bakouny and T. K. Choueiri, “IL-8 and Cancer Prognosis on Immunotherapy,” Nature Medicine 26, no. 5 (2020): 650–651.

[98] K. Fousek, L. A. Horn, and C. Palena, “Interleukin-8: A Chemokine At the Intersection of Cancer Plasticity, Angiogenesis, and Immune Suppression,” Pharmacology & Therapeutics 219 (2021): 107692.

[99] N. Song, P. Xie, W. Shen, et al., “A Microwell-Based Impedance Sensor on An Insertable Microneedle for Real-Time In Vivo Cytokine Detection,” Microsystems & Nanoengineering 7, no. 1 (2021): 96.

[100] Y. Wang, M. Wang, H. X. Wu, and R. H. Xu, “Advancing to the Era of Cancer Immunotherapy,” Cancer Communications 41, no. 9 (2021): 803–829.

[101] A. D. Waldman, J. M. Fritz, and M. J. Lenardo, “A Guide to Cancer Immunotherapy: From T Cell Basic Science to Clinical Practice,” Nature Reviews Immunology 20, no. 11 (2020): 651–668.

[102] S. Klobuch, T. T. P. Seijkens, T. N. Schumacher, and J. B. A. G. Haanen, “Tumour-Infiltrating Lymphocyte Therapy for Patients With Advanced-Stage Melanoma,” Nature Reviews Clinical Oncology 21, no. 3 (2024): 173–184.

[103] A. N. Khan, S. Asija, J. Pendhari, and R. Purwar, “CAR-T Cell Therapy in Hematological Malignancies: Where Are We Now and Where Are We Heading For?,” European Journal of Haematology 112, no. 1 (2024): 6–18.

[104] S. Bagchi, R. Yuan, and E. G. Engleman, “Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance,” Annual Review of Pathology: Mechanisms of Disease 16, no. Volume 16, 2021 (2021): 223–249.

[105] Y. Shiravand, F. Khodadadi, S. M. A. Kashani, et al., “Immune Checkpoint Inhibitors in Cancer Therapy,” Current Oncology 29, no. 5 (2022): 3044–3060.

[106] M. Saxena, S. H. van der Burg, C. J. M. Melief, and N. Bhardwaj, “Therapeutic Cancer Vaccines,” Nature Reviews Cancer 21, no. 6 (2021): 360–378.

[107] S. H. Joo, J. Kim, J. Hong, S. Fakhraei Lahiji, and Y. H. Kim, “Dissolvable Self-Locking Microneedle Patches Integrated With Immunomodulators for Cancer Immunotherapy,” Advanced Materials 35, no. 10 (2023): 2209966.

[108] X. C. Jiang, T. Zhang, and J. Q. Gao, “The In Vivo Fate and Targeting Engineering of Crossover Vesicle-Based Gene Delivery System,” Advanced Drug Delivery Reviews 187 (2022): 114324.

[109] X. Song, C. Liu, N. Wang, et al., “Delivery of CRISPR/Cas Systems for Cancer Gene Therapy and Immunotherapy,” Advanced Drug Delivery Reviews 168 (2021): 158–180.

[110] E. B. Yahya and A. M. Alqadhi, “Recent Trends in Cancer Therapy: A Review on the Current State of Gene Delivery,” Life Sciences 269 (2021): 119087.

[111] R. Mohammadinejad, A. Dehshahri, V. Sagar Madamsetty, et al., “In Vivo Gene Delivery Mediated by Non-viral Vectors for Cancer Therapy,” Journal of Controlled Release 325 (2020): 249–275.

[112] P. Singh, I. Muhammad, N. E. Nelson, et al., “Transdermal Delivery for Gene Therapy,” Drug Delivery and Translational Research 12, no. 11 (2022): 2613–2633.

[113] H. Shi, T. Xue, Y. Yang, et al., “Microneedle-Mediated Gene Delivery for the Treatment of Ischemic Myocardial Disease,” Science Advances 6, no. 25 (2020): eaaz3621.

[114] S. W. Wang, C. Gao, Y. M. Zheng, et al., “Current Applications and Future Perspective of CRISPR/Cas9 Gene Editing in Cancer,” Molecular Cancer 21, no. 1 (2022): 57.

[115] Z. Liu, M. Shi, Y. Ren, et al., “Recent Advances and Applications of CRISPR-Cas9 in Cancer Immunotherapy,” Molecular Cancer 22, no. 1 (2023): 35.

[116] G. B. Fard, M. H. Ahmadi, M. Gholamin, et al., “CRISPR-Cas9 Technology: As an Efficient Genome Modification Tool in the Cancer Diagnosis and Treatment,” Current Molecular Medicine 121 (2024): 472–488.

[117] N. Song, X. Fan, X. Guo, et al., “A DNA/Upconversion Nanoparticle Complex Enables Controlled Co-Delivery of CRISPR-Cas9 and Photodynamic Agents for Synergistic Cancer Therapy,” Advanced Materials 36, no. 15 (2024): e2309534.

[118] T. Wang, G. Chen, S. Zhang, et al., “Steerable Microneedles Enabling Deep Delivery of Photosensitizers and CRISPR/Cas9 Systems for Effective Combination Cancer Therapy,” Nano Letters 23, no. 17 (2023): 7990–7999.

[119] Y. Choi, S. H. Seok, H. Y. Yoon, J. H. Ryu, and I. C. Kwon, “Advancing Cancer Immunotherapy Through siRNA-Based Gene Silencing for Immune Checkpoint Blockade,” Advanced Drug Delivery Reviews 209 (2024): 115306.

[120] D. Hattab, A. M. Gazzali, and A. Bakhtiar, “Clinical Advances of siRNA-Based Nanotherapeutics for Cancer Treatment,” Pharmaceutics 13, no. 7 (2021): 1009.

[121] D. N. Yadav, M. S. Ali, A. M. Thanekar, S. V. Pogu, and A. K. Rengan, “Recent Advancements in the Design of Nanodelivery Systems of siRNA for Cancer Therapy,” Molecular Pharmaceutics 19, no. 12 (2022): 4506–4526.

[122] Y. Chen, Y. Huang, Q. Li, et al., “Targeting Xkr8 via Nanoparticle-Mediated in Situ Co-Delivery of siRNA and Chemotherapy Drugs for Cancer Immunochemotherapy,” Nature Nanotechnology 18, no. 2 (2023): 193–204.

[123] T. Yang, D. Huang, C. Li, et al., “Rolling Microneedle Electrode Array (RoMEA) Empowered Nucleic Acid Delivery and Cancer Immunotherapy,” Nano Today 36 (2021): 101017.

[124] V. Malhotra and M. C. Perry, “Classical Chemotherapy: Mechanisms, Toxicities and the Therapeutc Window,” Cancer Biology & Therapy 2, no. 4 Suppl 1 (2003): S2–S4.

[125] K. Nurgali, R. T. Jagoe, and R. Abalo, “Editorial: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae?,” Frontiers in Pharmacology 9 (2018): 245.

[126] B. Brianna and S. H. Lee, “Chemotherapy: How to Reduce Its Adverse Effects While Maintaining the Potency?,” Medical Oncology 40, no. 3 (2023): 88.

[127] M. J. Hassett, A. J. O'Malley, J. R. Pakes, J. P. Newhouse, and C. C. Earle, “Frequency and Cost of Chemotherapy-Related Serious Adverse Effects in a Population Sample of Women With Breast Cancer,” JNCI: Journal of the National Cancer Institute 98, no. 16 (2006): 1108–1117.

[128] H. Kim, H. S. Lee, Y. Jeon, et al., “Bioresorbable, Miniaturized Porous Silicon Needles on a Flexible Water-Soluble Backing for Unobtrusive, Sustained Delivery of Chemotherapy,” ACS Nano 14, no. 6 (2020): 7227–7236.

[129] D. Huang, X. Fu, X. Zhang, and Y. Zhao, “Christmas Tree-Shaped Microneedles as FOLFIRINOX Spatiotemporal Delivery System for Pancreatic Cancer Treatment,” Research 2022 (2022): 9809417.

[130] X. Hu, H. Li, R. Li, et al., “A Phase-Change Mediated Intelligent Nanoplatform for Chemo/Photothermal/Photodynamic Therapy of Cancer,” Advanced Healthcare Materials 12, no. 5 (2023): e2202245.

[131] C. G. Alves, R. Lima-Sousa, D. de Melo-Diogo, R. O. Louro, and I. J. Correia, “IR780 Based Nanomaterials for Cancer Imaging and Photothermal, Photodynamic and Combinatorial Therapies,” International Journal of Pharmaceutics 542, no. 1 (2018): 164–175.

[132] B. Nasseri, E. Alizadeh, F. Bani, et al., “Nanomaterials for Photothermal and Photodynamic Cancer Therapy,” Applied Physics Reviews 9, no. 1 (2022): 011317.

[133] Y. Sun, M. Chen, D. Yang, et al., “Self-Assembly Nanomicelle-Microneedle Patches With Enhanced Tumor Penetration for Superior Chemo-Photothermal Therapy,” Nano Research 15, no. 3 (2022): 2335–2346.

[134] G. He, Y. Li, M. R. Younis, et al., “Synthetic Biology-Instructed Transdermal Microneedle Patch for Traceable Photodynamic Therapy,” Nature Communications 13, no. 1 (2022): 6238.

[135] Y. Zhang, C. Liu, Z. Li, et al., “Microneedle-Mediated Synergistic Photothermal and Chemotherapy for Targeted Melanoma Treatment,” ACS Applied Materials & Interfaces 17, no. 10 (2025): 14952–14967.

[136] Y. Yin, L. Tang, Y. Cao, et al., “Microneedle Patch-Involved Local Therapy Synergized With Immune Checkpoint Inhibitor for Pre- and Post-Operative Cancer Treatment,” Journal of Controlled Release 379 (2025): 678–695.

[137] S. Huang, T. Wen, J. Wang, et al., “Nanoparticle-Integrated Dissolving Microneedles for the Co-Delivery of R848/aPD-1 to Synergistically Reverse the Immunosuppressive Microenvironment of Triple-Negative Breast Cancer,” Acta Biomaterialia 176 (2024): 344–355.

[138] J. A. Paice and B. Ferrell, “The Management of Cancer Pain,” CA: A Cancer Journals for Clinicians 61 (2011): 157–182.

[139] M. Evenepoel, V. Haenen, T. De Baerdemaecker, et al., “Pain Prevalence During Cancer Treatment: A Systematic Review and Meta-Analysis,” Journal of Pain and Symptom Management 63, no. 3 (2022): e317–e335.

[140] S. Mercadante, “Opioid Dose Titration for Cancer Pain,” European Journal of Pain 28, no. 3 (2024): 359–368.

[141] F. Mestdagh, A. Steyaert, and P. Lavand'homme, “Cancer Pain Management: A Narrative Review of Current Concepts, Strategies, and Techniques,” Current Oncology 30, no. 7 (2023): 6838–6858.

[142] E. Bruera and J. A. Paice, “Cancer Pain Management: Safe and Effective Use of Opioids,” American Society of Clinical Oncology Educational Book 1 (2015): e593–e599.

[143] P. J. Wiffen, B. Wee, S. Derry, et al., “Opioids for Cancer Pain - An Overview of Cochrane Reviews,” Cochrane Database of Systematic Reviews 7 (2017): CD012592.

[144] J. Vardy and M. Agar, “Nonopioid Drugs in the Treatment of Cancer Pain,” Journal of Clinical Oncology 32, no. 16 (2014): 1677–1690.

[145] C. Sostres, C. J. Gargallo, M. T. Arroyo, and A. Lanas, “Adverse Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDS, Aspirin and Coxibs) on Upper Gastrointestinal Tract,” Best Practice & Research Clinical Gastroenterology 24, no. 2 (2010): 121–132.

[146] H. E. Vonkeman and M. A. F. J. van de Laar, “Nonsteroidal Anti-Inflammatory Drugs: Adverse Effects and Their Prevention,” Seminars in Arthritis and Rheumatism 39, no. 4 (2010): 294–312.

[147] M. Camilleri, A. Lembo, and D. A. Katzka, “Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits,” Clinical Gastroenterology and Hepatology 15, no. 9 (2017): 1338–1349.

[148] S. Mercadante, “Opioid Analgesics Adverse Effects: The Other Side of the Coin,” Current Pharmaceutical Design 25, no. 30 (2019): 3197–3202.

[149] A. K. Paul, C. M. Smith, M. Rahmatullah, et al., “Opioid Analgesia and Opioid-Induced Adverse Effects: A Review,” Pharmaceuticals 14, no. 11 (2021): 1091.

[150] W. Leppert, M. Malec–Milewska, R. Zajaczkowska, and J. Wordliczek, “Transdermal and Topical Drug Administration in the Treatment of Pain,” Molecules 23, no. 3 (2018): 681.

[151] T. Benbow and J. Campbell, “Microemulsions as Transdermal Drug Delivery Systems for Nonsteroidal Anti-Inflammatory Drugs (NSAIDS): A Literature Review,” Drug Development and Industrial Pharmacy 45, no. 12 (2019): 1849–1855.

[152] L. Kumar, S. Verma, M. Singh, T. Chalotra, and P. Utreja, “Advanced Drug Delivery Systems for Transdermal Delivery of Non-Steroidal Anti-Inflammatory Drugs: A Review,” Current Drug Delivery 15, no. 8 (2018): 1087–1099.

[153] L. Margetts and R. Sawyer, “Transdermal Drug Delivery: Principles and Opioid Therapy,” Continuing Education in Anaesthesia Critical Care & Pain 7, no. 5 (2007): 171–176.

[154] S. Khuangsirikul, M. Pisuttanawat, D. Heebthamai, and T. Chotanaphuti, “Effect of Transdermal Microneedle Patch With NSAID in Osteoarthritic Knee,” Osteoarthritis and Cartilage 30 (2022): S69.

[155] J. Wang, J. Zeng, Z. Liu, et al., “Promising Strategies for Transdermal Delivery of Arthritis Drugs: Microneedle Systems,” Pharmaceutics 14, no. 8 (2022): 1736.

[156] F. Yang, W. Wang, J. Zhou, et al., “Transdermal Delivery of IBU-PLGA Nanoparticles With Dissolving Microneedle Array Patch,” Journal of Drug Delivery Science and Technology 95 (2024): 105528.

[157] J. Chen, W. Huang, Z. Huang, et al., “Fabrication of Tip-Dissolving Microneedles for Transdermal Drug Delivery of Meloxicam,” AAPS PharmSciTech 19, no. 3 (2018): 1141–1151.

[158] A. Sadeqi, G. Kiaee, W. Zeng, H. Rezaei Nejad, and S. Sonkusale, “Hard Polymeric Porous Microneedles on Stretchable Substrate for Transdermal Drug Delivery,” Scientific Reports 12, no. 1 (2022): 1853.

[159] A. Maurya, S. Rangappa, J. Bae, T. Dhawan, S. S. Ajjarapu, and S. N. Murthy, “Evaluation of Soluble Fentanyl Microneedles for Loco-Regional Anti-Nociceptive Activity,” International Journal of Pharmaceutics 564 (2019): 485–491.

[160] P. Hesketh, D. Batchelor, M. Golant, G. Lyman, N. Rhodes, and D. Yardley, “Chemotherapy-Induced Alopecia: Psychosocial Impact and Therapeutic Approaches,” Supportive Care in Cancer 12, no. 8 (2004): 543–549.

[161] A. Rossi, M. C. Fortuna, G. Caro, et al., “Chemotherapy-Induced Alopecia Management: Clinical Experience and Practical Advice,” Journal of Cosmetic Dermatology 16, no. 4 (2017): 537–541.

[162] C. Prevezas, B. Matard, L. Pinquier, and P. Reygagne, “Irreversible and Severe Alopecia Following Docetaxel or Paclitaxel Cytotoxic Therapy for Breast Cancer,” British Journal of Dermatology 160, no. 4 (2009): 883–885.

[163] J. Chan, H. Adderley, M. Alameddine, et al., “Permanent Hair Loss Associated With Taxane Chemotherapy Use in Breast Cancer: A Retrospective Survey At Two Tertiary UK Cancer Centres,” European Journal of Cancer Care 30, no. 3 (2021): e13395.

[164] M. de Jonge, R. Mathôt, O. Dalesio, A. Huitema, S. Rodenhuis, and J. Beijnen, “Relationship Between Irreversible Alopecia and Exposure to Cyclophosphamide, Thiotepa and Carboplatin (CTC) in High-Dose Chemotherapy,” Bone Marrow Transplantation 30, no. 9 (2002): 593–597.

[165] E. Haque, M. S. Alabdaljabar, K. J. Ruddy, et al., “Management of Chemotherapy-Induced Alopecia (CIA): A Comprehensive Review and Future Directions,” Critical Reviews in Oncology/Hematology 156 (2020): 103093.

[166] T. C. Wikramanayake, N. I. Haberland, A. Akhundlu, A. Laboy Nieves, and M. Miteva, “Prevention and Treatment of Chemotherapy-Induced Alopecia: What Is Available and What Is Coming?,” Current Oncology 30, no. 4 (2023): 3609–3626.

[167] N. Natarelli, N. Gahoonia, and R. K. Sivamani, “Integrative and Mechanistic Approach to the Hair Growth Cycle and Hair Loss,” Journal of Clinical Medicine 12, no. 3 (2023): 893.

[168] S. Quesada, A. Guichard, and F. Fiteni, “Cancer-Related Alopecia: From Etiologies to Global Management,” Cancers 13, no. 21 (2021): 5556.

[169] C. Goh, “Permanent Alopecia in Breast Cancer Patients: Role of Taxanes and Endocrine Therapies,” Cutis 107, no. 3 (2021): E17–E22.

[170] A. Lyakhovitsky, O. Segal, A. Maly, A. Zlotogorski, and A. Barzilai, “Permanent Chemotherapy-Induced Alopecia After Hematopoietic Stem Cell Transplantation Treated With Low-Dose Oral Minoxidil,” JAAD Case Reports 22 (2022): 64–67.

[171] B. Y. Choi, “Targeting Wnt/β-Catenin Pathway for Developing Therapies for Hair Loss,” International Journal of Molecular Sciences 21, no. 14 (2020): 4915.

[172] R. Li, X. Yuan, L. Zhang, et al., “3D Printing of Microneedle Arrays for Hair Regeneration in a Controllable Region,” Molecular Biomedicine 4, no. 1 (2023): 1.

[173] S. Y. Chu, C. H. Chou, H. D. Huang, et al., “Mechanical Stretch Induces Hair Regeneration Through the Alternative Activation of Macrophages,” Nature Communications 10, no. 1 (2019): 1524.

[174] C. C. Chen, L. Wang, M. V. Plikus, et al., “Organ-Level Quorum Sensing Directs Regeneration in Hair Stem Cell Populations,” Cell 161, no. 2 (2015): 277–290.

[175] B. Zheng, L. Yang, S. Feng, et al., “Organoid-Loaded Cryomicroneedles for Biomimic Hair Regeneration,” Advanced Functional Materials 34, no. 3 (2024): 2304950.

[176] Z. Kanaki, A. Smina, C. Chandrinou, et al., “Printed Cisplatin on Microneedle Arrays for Transdermal Delivery Enhances Olaparib-Induced Synthetic Lethality in a Mouse Model of Homologous Recombination Deficiency,” International Journal of Bioprinting 9, no. 6 (2023): 0048.

[177] R. Zhou, H. Yu, T. Sheng, et al., “Grooved Microneedle Patch Augments Adoptive T Cell Therapy Against Solid Tumors via Diverting Regulatory T Cells,” Advanced Materials 36, no. 30 (2024): e2401667.

[178] M. Xiang, C. Yang, L. Zhang, S. Wang, Y. Ren, and M. Gou, “Dissolving Microneedles for Transdermal Drug Delivery in Cancer Immunotherapy,” Journal of Materials Chemistry B 12, no. 24 (2024): 5812–5822.

[179] C. Wang, G. He, H. Zhao, Y. Lu, P. Jiang, and W. Li, “Enhancing Deep-Seated Melanoma Therapy Through Wearable Self-Powered Microneedle Patch,” Advanced Materials 36, no. 11 (2024): e2311246.

[180] H. Chu, J. Xue, Y. Yang, H. Zheng, D. Luo, and Z. Li, “Advances of Smart Stimulus-Responsive Microneedles in Cancer Treatment,” Small Methods 8, no. 9 (2024): e2301455.

[181] P. Sun, L. Huang, Z. Li, et al., “Charge-Reversal Biodegradable Nanoplatform With Ferroptosis and ICD Induction for Tumor Synergistic Treatment,” Chemical Engineering Journal 483 (2024): 149234.

[182] A. Bakshi, R. Shafi, J. Nelson, et al., “The Clinical Course of Actinic Keratosis Correlates With Underlying Molecular Mechanisms,” British Journal of Dermatology 182, no. 4 (2020): 995–1002.

[183] B. Worley, V. Harikumar, K. Reynolds, et al., “Treatment of Actinic Keratosis: A Systematic Review,” Archives of Dermatological Research 315, no. 5 (2023): 1099–1108.

[184] L. Kandolf, K. Peris, J. Malvehy, et al., “European consensus-based interdisciplinary guideline for diagnosis, treatment and prevention of actinic keratoses, epithelial UV-induced dysplasia and field cancerization on behalf of European Association of Dermato-Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology and Union of Medical Specialists (Union Européenne des Médecins Spécialistes),” Journal of the European Academy of Dermatology and Venereology 38 (2024): 1024–1047.

[185] T. A. Petukhova, L. A. Hassoun, N. Foolad, M. Barath, and R. K. Sivamani, “Effect of Expedited Microneedle-Assisted Photodynamic Therapy for Field Treatment of Actinic Keratoses: A Randomized Clinical Trial,” JAMA Dermatology 153, no. 7 (2017): 637.

[186] S. Wang, M. Zhao, Y. Yan, P. Li, and W. Huang, “Flexible Monitoring, Diagnosis, and Therapy by Microneedles With Versatile Materials and Devices Toward Multifunction Scope,” Research 6 (2023): 0128.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm – Biomaterials and Applications published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).